Merck
HomeWebinarsAchieving High Yields in Scalable Xeno-Free Culture Formats with Mesenchymal Stem Cell Medium

Achieving High Yields in Scalable Xeno-Free Culture Formats with Mesenchymal Stem Cell Medium



WEBINAR

Optimizing ex vivo cell expansion processes in preparation for clinical use is a critical step in cell therapy manufacturing. Given the curative and lifesaving impacts these therapies can have on patients, overcoming roadblocks with scalability and supply chain, using high-quality raw materials are essential for therapeutic access.

The GMP-compliant Stemline® XF MSC Medium and cocktail promote the expansion of human mesenchymal stromal/stem cells (hMSCs) to high densities while maintaining cell identity and quality. This product was designed for derivation and expansion of MSCs using xeno-free conditions in planar and microcarrier-based culture platforms, easing the transfer between research, clinical, and manufacturing scale cultures.

In this webinar, you will:

  • Explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells
  • Discover ways to derive MSCs from bone marrow in xeno-free conditions from static to microcarrier-based suspension culture platforms.
  • Learn how Stemline® XF MSC Media provides robust performance and reduces scalability roadblocks

Speakers

Kathleen Ongena, Ph.D.

Kathleen Ongena, Ph.D.

Merck

Head of Customer Applications

Kathleen Ongena has been part of {hcampany} for more than 10 years. She currently manages contract research projects and media development in the cell therapy bioprocessing group, providing expertise in cell culture, media formulation, product and assay development. Kathleen’s previous roles have included R&D scientist and R&D manager in our research solution business. As an R&D manager, she was responsible for developing and driving the technical strategic roadmap for the cell culture systems franchise. She led the application development and validation for multiple products within this franchise. Kathleen earned her Ph.D. from the University of Leuven, Belgium in the fields of molecular and cell biology generating transgenic mouse models to study psoriasis.

Mark Ventresco

Mark Ventresco

Merck

Cell Therapy Product Manager

Mark Ventresco is a product manager supporting the cell therapy manufacturing portfolio. In his role, Mark manages the Stemline® media portfolio, consisting of various expansion and maturation cell culture media optimized for clinical and manufacturing environments. He also supports new product development initiatives including cell therapy manufacturing systems. Mark holds a B.S in chemical engineering and an M.S. in plastic engineering.